Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

Published:2016-09-30 Issue:12 Volume:65 Page:1523-1532
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Wang Wei,Erbe Amy K.,Gallenberger Mikayla,Kim KyungMann,Carmichael Lakeesha,Hess Dustin,Mendonca Eneida A.,Song Yiqiang,Hank Jacquelyn A.,Cheng Su-Chun,Signoretti Sabina,Atkins Michael,Carlson Alexander,Weiss Jonathan M.,Mier James,Panka David,McDermott David F.,Sondel Paul M.

Funder

Hyundai Hope on Wheels Grant

Midwest Athletes Against Childhood

Stand Up 2 Cancer

The St. Baldrick’s Foundation

American Association of Cancer Research

University of Wisconsin-Madison Carbone Cancer Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1904-8.pdf

Reference38 articles.

1. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncol (Williston Park) 23(6):488–496

2. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB (2015) The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21(3):561–568. doi: 10.1158/1078-0432.CCR-14-1520

3. Gasser S, Raulet DH (2006) Activation and self-tolerance of natural killer cells. Immunol Rev 214:130–142. doi: 10.1111/j.1600-065X.2006.00460.x

4. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fc receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554–9561. doi: 10.1158/0008-5472.can-10-2211

5. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2(9):878–889. doi: 10.1158/2326-6066.cir-13-0158

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial;Cancer Immunology, Immunotherapy;2023-02-23

2. Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer;Annals of Translational Medicine;2020-03

3. NK Cell-Based Immunotherapy in Renal Cell Carcinoma;Cancers;2020-01-29

4. Emerging targets in cancer immunotherapy;Seminars in Cancer Biology;2018-10

5. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy;Frontiers in Immunology;2017-06-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3